Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Bookmark and Share
Published: 9 Oct 2016
Views: 2197
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Dr Barlesi presents, at a press conference at ESMO 2016, results from the OAK study, which found atezolizumab improved median overall survival for patients with advanced non-small cell lung cancer, especially those stratified by high PD-1 expression.

His interview with ecancer about the results is available here.

PD-1/PD-L1 targeting in lung cancer was also the focus of ESMO 2016 presentations from Dr Corey Langer, in which first-line pembrolizmab plus chemotherapy improved patient outcomes, and Dr Martin Reck, who reported on using pembrolizumab as a first line single-agent treatment.